デフォルト表紙
市場調査レポート
商品コード
1530917

酵素阻害剤市場:世界の産業分析、規模、シェア、成長、動向、2024~2034年予測

Enzyme Inhibitor Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034


出版日
ページ情報
英文 203 Pages
納期
2~10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
酵素阻害剤市場:世界の産業分析、規模、シェア、成長、動向、2024~2034年予測
出版日: 2024年06月07日
発行: Transparency Market Research
ページ情報: 英文 203 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

酵素阻害剤市場-調査範囲

TMRの調査レポート「酵素阻害剤の世界市場」は、2024~2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018~2034年までの世界の酵素阻害剤市場の収益と予測を提供しています。また、2024~2034年までの世界の酵素阻害剤市場の複合年間成長率(CAGR %)も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、酵素阻害剤市場を推察しました。

市場スナップショット
2023年の市場規模 28億米ドル
2034年の市場規模 59億米ドル
CAGR 7.1%

当レポートでは、世界の酵素阻害剤市場の競合情勢について調査しています。世界の酵素阻害剤市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の酵素阻害剤市場における参入企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー:市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 市場分析と予測、2020~2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品・ブランド分析
  • 主要M&A
  • COVID-19による産業への影響

第6章 世界の市場分析と予測:製品タイプ別

  • イントロダクションと定義
  • 主要調査結果・発展
  • 市場金額予測:製品タイプ別、2020~2034年
    • 低分子阻害剤
    • モノクローナル抗体
    • RNAベースの阻害剤
    • その他
  • 市場の魅力:製品タイプ別分析

第7章 世界の市場分析と予測:治療領域別

  • イントロダクションと定義
  • 主要調査結果・発展
  • 市場金額予測:治療領域別、2020~2034年
    • 腫瘍学
    • 心血管疾患
    • 感染症
    • 自己免疫疾患
    • その他
  • 市場の魅力分析:治療領域別

第8章 世界の市場分析と予測:エンドユーザー別

  • イントロダクションと定義
  • 主要調査結果・発展
  • 市場金額予測:エンドユーザー別、2020~2034年
    • 製薬会社
    • バイオテクノロジー企業
    • 学術研究機関
  • 市場の魅力分析:エンドユーザー別

第9章 世界の市場分析と予測:地域別

  • 主要調査結果
  • 市場金額予測:地域別、2020~2034年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析:地域別

第10章 北米の市場分析と予測

第11章 欧州の市場分析と予測

第12章 アジア太平洋の市場分析と予測

第13章 ラテンアメリカ市場分析と予測

第14章 中東・アフリカの市場分析と予測

第15章 競合情勢

  • 市場企業-競争マトリックス(企業階層と規模別)
  • 市場シェア分析:企業別(2023年)
  • 企業プロファイル
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Bayer AG
    • AstraZeneca plc
    • GSK plc
    • AbbVie Inc.
    • Bristol Myers Squibb Company
図表

List of Tables

  • Table 01: Global Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 02: Global Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Therapeutic Area, 2020-2034
  • Table 03: Global Enzyme Inhibitor Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 04: Global Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 05: North America Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 06: North America Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 07: North America Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Therapeutic Area, 2020-2034
  • Table 08: North America Enzyme Inhibitor Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 09: Europe Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 11: Europe Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Therapeutic Area, 2020-2034
  • Table 12: Europe Enzyme Inhibitor Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 13: Asia Pacific Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 15: Asia Pacific Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Therapeutic Area, 2020-2034
  • Table 16: Asia Pacific Enzyme Inhibitor Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 17: Latin America Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 19: Latin America Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Therapeutic Area, 2020-2034
  • Table 20: Latin America Enzyme Inhibitor Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 21: Middle East & Africa Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Product Type, 2020-2034
  • Table 23: Middle East & Africa Enzyme Inhibitor Market Size (US$ Bn) Forecast, by Therapeutic Area, 2020-2034
  • Table 24: Middle East & Africa Enzyme Inhibitor Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Enzyme Inhibitor Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Enzyme Inhibitor Market Revenue (US$ Bn), by Product Type, 2023
  • Figure 03: Global Enzyme Inhibitor Market Value Share, by Product Type, 2023
  • Figure 04: Global Enzyme Inhibitor Market Revenue (US$ Bn), by Therapeutic Area, 2023
  • Figure 05: Global Enzyme Inhibitor Market Value Share, by Therapeutic Area, 2023
  • Figure 06: Global Enzyme Inhibitor Market Revenue (US$ Bn), by End-user, 2023
  • Figure 07: Global Enzyme Inhibitor Market Value Share, by End-user, 2023
  • Figure 08: Global Enzyme Inhibitor Market Value Share, by Region, 2023
  • Figure 09: Global Enzyme Inhibitor Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 10: Global Enzyme Inhibitor Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 11: Global Enzyme Inhibitor Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Enzyme Inhibitor Market Value Share Analysis, by Therapeutic Area, 2023 and 2034
  • Figure 13: Global Enzyme Inhibitor Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
  • Figure 14: Enzyme Inhibitor Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 15: Global Enzyme Inhibitor Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 16: Global Enzyme Inhibitor Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Enzyme Inhibitor Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Enzyme Inhibitor Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Enzyme Inhibitor Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Enzyme Inhibitor Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Enzyme Inhibitor Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 22: North America Enzyme Inhibitor Market Value Share Analysis, by Therapeutic Area, 2023 and 2034
  • Figure 23: North America Enzyme Inhibitor Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 24: North America Enzyme Inhibitor Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Enzyme Inhibitor Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
  • Figure 26: North America Enzyme Inhibitor Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 27: Europe Enzyme Inhibitor Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Enzyme Inhibitor Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Enzyme Inhibitor Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Enzyme Inhibitor Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 31: Europe Enzyme Inhibitor Market Value Share Analysis, by Therapeutic Area, 2023 and 2034
  • Figure 32: Europe Enzyme Inhibitor Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 33: Europe Enzyme Inhibitor Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Enzyme Inhibitor Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
  • Figure 35: Europe Enzyme Inhibitor Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 36: Asia Pacific Enzyme Inhibitor Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Enzyme Inhibitor Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Enzyme Inhibitor Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Enzyme Inhibitor Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 40: Asia Pacific Enzyme Inhibitor Market Value Share Analysis, by Therapeutic Area, 2023 and 2034
  • Figure 41: Asia Pacific Enzyme Inhibitor Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 42: Asia Pacific Enzyme Inhibitor Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Enzyme Inhibitor Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
  • Figure 44: Asia Pacific Enzyme Inhibitor Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 45: Latin America Enzyme Inhibitor Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Enzyme Inhibitor Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Enzyme Inhibitor Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Enzyme Inhibitor Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 49: Latin America Enzyme Inhibitor Market Value Share Analysis, by Therapeutic Area, 2023 and 2034
  • Figure 50: Latin America Enzyme Inhibitor Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Latin America Enzyme Inhibitor Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Enzyme Inhibitor Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
  • Figure 53: Latin America Enzyme Inhibitor Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 54: Middle East & Africa Enzyme Inhibitor Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Enzyme Inhibitor Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Enzyme Inhibitor Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Enzyme Inhibitor Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 58: Middle East & Africa Enzyme Inhibitor Market Value Share Analysis, by Therapeutic Area, 2023 and 2034
  • Figure 59: Middle East & Africa Enzyme Inhibitor Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 60: Middle East & Africa Enzyme Inhibitor Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Enzyme Inhibitor Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
  • Figure 62: Middle East & Africa Enzyme Inhibitor Market Attractiveness Analysis, by End-user, 2024-2034
目次
Product Code: TMRGL135

Enzyme Inhibitor Market - Scope of Report

TMR's report on the global enzyme inhibitor market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global enzyme inhibitor market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global enzyme inhibitor market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the enzyme inhibitor market.

Market Snapshot
Market Value in 2023US$ 2.8 Bn
Market Value in 2034US$ 5.9 Bn
CAGR7.1%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global enzyme inhibitor market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global enzyme inhibitor market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global enzyme inhibitor market.

The report delves into the competitive landscape of the global enzyme inhibitor market. Key players operating in the global enzyme inhibitor market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global enzyme inhibitor market profiled in this report.

Key Questions Answered in Global enzyme inhibitor Market Report:

  • What is the sales/revenue generated by enzyme inhibitor across all regions during the forecast period?
  • What are the opportunities in the global enzyme inhibitor market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Enzyme Inhibitor Market - Research Objectives and Research Approach

The comprehensive report on the global enzyme inhibitor market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global enzyme inhibitor market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global enzyme inhibitor market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Enzyme Inhibitor Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Enzyme Inhibitor Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Enzyme Inhibitor Market Analysis and Forecast, by Product Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product Type, 2020-2034
    • 6.3.1. Small Molecule Inhibitors
    • 6.3.2. Monoclonal Antibodies
    • 6.3.3. RNA-based Inhibitors
    • 6.3.4. Others
  • 6.4. Market Attractiveness Analysis, by Product Type

7. Global Enzyme Inhibitor Market Analysis and Forecast, by Therapeutic Area

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Therapeutic Area, 2020-2034
    • 7.3.1. Oncology
    • 7.3.2. Cardiovascular Diseases
    • 7.3.3. Infectious Diseases
    • 7.3.4. Autoimmune Disorders
    • 7.3.5. Others
  • 7.4. Market Attractiveness Analysis, by Therapeutic Area

8. Global Enzyme Inhibitor Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2020-2034
    • 8.3.1. Pharmaceutical Companies
    • 8.3.2. Biotechnology Companies
    • 8.3.3. Academic and Research Institutes
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Enzyme Inhibitor Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Enzyme Inhibitor Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Product Type, 2020-2034
    • 10.3.1. Small Molecule Inhibitors
    • 10.3.2. Monoclonal Antibodies
    • 10.3.3. RNA-based Inhibitors
    • 10.3.4. Others
  • 10.4. Market Value Forecast, by Therapeutic Area, 2020-2034
    • 10.4.1. Oncology
    • 10.4.2. Cardiovascular Diseases
    • 10.4.3. Infectious Diseases
    • 10.4.4. Autoimmune Disorders
    • 10.4.5. Others
  • 10.5. Market Value Forecast, by End-user, 2020-2034
    • 10.5.1. Pharmaceutical Companies
    • 10.5.2. Biotechnology Companies
    • 10.5.3. Academic and Research Institutes
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Product Type
    • 10.7.2. By Therapeutic Area
    • 10.7.3. By End-user
    • 10.7.4. By Country

11. Europe Enzyme Inhibitor Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Product Type, 2020-2034
    • 11.3.1. Small Molecule Inhibitors
    • 11.3.2. Monoclonal Antibodies
    • 11.3.3. RNA-based Inhibitors
    • 11.3.4. Others
  • 11.4. Market Value Forecast, by Therapeutic Area, 2020-2034
    • 11.4.1. Oncology
    • 11.4.2. Cardiovascular Diseases
    • 11.4.3. Infectious Diseases
    • 11.4.4. Autoimmune Disorders
    • 11.4.5. Others
  • 11.5. Market Value Forecast, by End-user, 2020-2034
    • 11.5.1. Pharmaceutical Companies
    • 11.5.2. Biotechnology Companies
    • 11.5.3. Academic and Research Institutes
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Product Type
    • 11.7.2. By Therapeutic Area
    • 11.7.3. By End-user
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Enzyme Inhibitor Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Product Type, 2020-2034
    • 12.3.1. Small Molecule Inhibitors
    • 12.3.2. Monoclonal Antibodies
    • 12.3.3. RNA-based Inhibitors
    • 12.3.4. Others
  • 12.4. Market Value Forecast, by Therapeutic Area, 2020-2034
    • 12.4.1. Oncology
    • 12.4.2. Cardiovascular Diseases
    • 12.4.3. Infectious Diseases
    • 12.4.4. Autoimmune Disorders
    • 12.4.5. Others
  • 12.5. Market Value Forecast, by End-user, 2020-2034
    • 12.5.1. Pharmaceutical Companies
    • 12.5.2. Biotechnology Companies
    • 12.5.3. Academic and Research Institutes
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Product Type
    • 12.7.2. By Therapeutic Area
    • 12.7.3. By End-user
    • 12.7.4. By Country/Sub-region

13. Latin America Enzyme Inhibitor Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Product Type, 2020-2034
    • 13.3.1. Small Molecule Inhibitors
    • 13.3.2. Monoclonal Antibodies
    • 13.3.3. RNA-based Inhibitors
    • 13.3.4. Others
  • 13.4. Market Value Forecast, by Therapeutic Area, 2020-2034
    • 13.4.1. Oncology
    • 13.4.2. Cardiovascular Diseases
    • 13.4.3. Infectious Diseases
    • 13.4.4. Autoimmune Disorders
    • 13.4.5. Others
  • 13.5. Market Value Forecast, by End-user, 2020-2034
    • 13.5.1. Pharmaceutical Companies
    • 13.5.2. Biotechnology Companies
    • 13.5.3. Academic and Research Institutes
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Product Type
    • 13.7.2. By Therapeutic Area
    • 13.7.3. By End-user
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Enzyme Inhibitor Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Product Type, 2020-2034
    • 14.3.1. Small Molecule Inhibitors
    • 14.3.2. Monoclonal Antibodies
    • 14.3.3. RNA-based Inhibitors
    • 14.3.4. Others
  • 14.4. Market Value Forecast, by Therapeutic Area, 2020-2034
    • 14.4.1. Oncology
    • 14.4.2. Cardiovascular Diseases
    • 14.4.3. Infectious Diseases
    • 14.4.4. Autoimmune Disorders
    • 14.4.5. Others
  • 14.5. Market Value Forecast, by End-user, 2020-2034
    • 14.5.1. Pharmaceutical Companies
    • 14.5.2. Biotechnology Companies
    • 14.5.3. Academic and Research Institutes
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Product Type
    • 14.7.2. By Therapeutic Area
    • 14.7.3. By End-user
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Merck & Co., Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Novartis AG
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Pfizer Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. F. Hoffmann-La Roche AG
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Bayer AG
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. AstraZeneca plc
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. GSK plc
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. AbbVie Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Bristol Myers Squibb Company
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview